Compare · MDLN vs SGP
MDLN vs SGP
Side-by-side comparison of Medline Inc. (MDLN) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 58.1x SGP ($826.8M).
- Over the past year, MDLN is down 11.8% and SGP is down 7.6% - SGP leads by 4.1 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 2 for SGP).
- MDLN has more recent analyst coverage (25 ratings vs 6 for SGP).
PerformanceMDLN-23.96%SGP-7.62%
2026-02-06+0.00%2026-10-16
- Company
- Medline Inc.
- SpyGlass Pharma Inc.
- Price
- $35.95-1.74%
- $24.12-1.59%
- Market cap
- $48.08B
- $826.8M
- 1M return
- +11.97%
- -17.57%
- 1Y return
- -11.77%
- -7.62%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2026
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 6
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest SGP
- SpyGlass Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- Raymond James initiated coverage on SpyGlass Pharma with a new price target
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- SpyGlass Pharma Appoints Shannon Treviño as General Counsel
- SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
- SpyGlass Pharma to Participate in Upcoming Investor Conferences